Dallan Murray joined Sarepta in 2013 as vice president, Marketing and was one of the first commercial hires at the Company. He was instrumental in building the commercial organization and launching Sarepta’s three approved RNA therapies, including one of the top-five most successful rare disease product launches in history.
“I was drawn to Sarepta by the meaningful mission, the cutting-edge science and the belief that the future of the industry is in the potential to transform lives through precision genetic medicine.”
In December 2020, Dallan was named senior vice president, chief commercial officer, overseeing Sarepta’s U.S. and Global Commercial Strategy and Operations, Global Market Access, Patient Services, and Payer & Distribution. Since then, and in addition to his current responsibilities, his role has evolved, and in November 2021 he was appointed Chief Customer Officer to reflect an enhanced model as Sarepta realizes the promise of its leading-edge technologies to serve rare disease patients around the world.
Dallan formerly served as Sarepta’s vice president, commercial strategy and portfolio management, overseeing the commercial positioning and readiness for the Company’s pipeline of more than 40 investigational therapies.
His scientific knowledge, his relationships with neuromuscular thought leaders and treating physicians around the world, and his insight in access and reimbursement make him uniquely suited for this role. Dallan’s commercial experience spans over 20 years and includes commercial leadership roles at Vertex Pharmaceuticals, Gilead Sciences, Biogen, and Janssen Ortho.
Dallan holds a Bachelor of Commerce degree from University of Alberta, and a Master’s in Business Administration from Queen’s University.
What is Dallan Murray's net worth?
The estimated net worth of Dallan Murray is at least $2.24 million as of May 2nd, 2024. Mr. Murray owns 18,125 shares of Sarepta Therapeutics stock worth more than $2,236,806 as of December 26th. This net worth approximation does not reflect any other investments that Mr. Murray may own. Learn More about Dallan Murray's net worth.
How do I contact Dallan Murray?
Has Dallan Murray been buying or selling shares of Sarepta Therapeutics?
Dallan Murray has not been actively trading shares of Sarepta Therapeutics within the last three months. Most recently, Dallan Murray sold 3,635 shares of the business's stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $140.00, for a transaction totalling $508,900.00. Following the completion of the sale, the insider now directly owns 18,125 shares of the company's stock, valued at $2,537,500. Learn More on Dallan Murray's trading history.
Who are Sarepta Therapeutics' active insiders?
Sarepta Therapeutics' insider roster includes Bilal Arif (EVP, Chief Technical Operations Officer), Richard Barry (Director), M. Behrens (Director), Kathryn Boor (Director), Joseph Bratica (Insider), Ryan Brown (EVP), Michael Chambers (Director), Ian Estepan (EVP, Chief Financial Officer), David Howton (EVP), Douglas Ingram (CEO), Stephen Mayo (Director), Dallan Murray (EVP, Chief Customer Officer), Louise Rodino-Klapac (Insider), and Hans Wigzell (Director). Learn More on Sarepta Therapeutics' active insiders.
Are insiders buying or selling shares of Sarepta Therapeutics?
In the last twelve months, Sarepta Therapeutics insiders bought shares 1 times. They purchased a total of 37,038 shares worth more than $4,955,684.40. In the last twelve months, insiders at the biotechnology company sold shares 11 times. They sold a total of 90,668 shares worth more than $13,164,125.22. The most recent insider tranaction occured on December, 12th when Director Hans Lennart Rudolf Wigzell sold 10,500 shares worth more than $1,310,820.00. Insiders at Sarepta Therapeutics own 7.7% of the company.
Learn More about insider trades at Sarepta Therapeutics. Information on this page was last updated on 12/12/2024.
